Evotec AG (investor - Corporate Investor)

See something wrong or missing? Let us know
Offices:Hamburg

Evotec SE is a publicly listed drug discovery and development company that operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists.

Average round investment:57.66M USD
Average number per year:1.2
Distribution: 2024 (2)2022 (1)2021 (1)2020 (1)2019 (1) See the entire list
Mostly invests in: United Kingdom United Kingdom (4) Biotech (7)
See the entire list

Showing 3 of 7 tracked investments in:


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Evotec AG mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Evotec AG

Name Criteria
United States SR One
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
United Kingdom 3i
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United Kingdom Medicxi
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Ireland
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States Thiel Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States What If Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Germany
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
China GT Healthcare Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Charles River Laboratories
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Ireland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Cowen Healthcare Investments
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Atlas Venture
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Italy
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
South Korea LG Electronics
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Germany
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Top